Vogl, NY: Adjuvant OFS for Resected Breast Cancer Revisited

After the results of the Eastern Cooperative Oncology Group (ECOG) 5188 study (Intergroup 0101) were published by Davidson et al,¹ many of us in the field hoped that a study of additional adjuvant ovarian function suppression (OFS) restricted to women with functioning ovaries would demonstrate clearly the benefit of OFS. No such study had ever been conducted in the era of adjuvant chemotherapy and tamoxifen (TAM).

SOFT